TransMedics Shares Drop 5% to $134.55
TransMedics shares are moving lower after Bridge to Life announced that the Food and Drug Administration has granted De Novo clearance for its VitaSmart Hypothermic Oxygenated Perfusion System. The clearance establishes a "new regulatory classification for hypothermic oxygenated perfusion in liver transplantation in the United States," the privately held company said in a statement. The FDA clearance enables the commercial use of VitaSmart for hypothermic oxygenated perfusion of donor livers following static cold storage and prior to transplantation. Shares of TransMedics are down 5%, or $7.38, to $134.55 following the news. TransMedics' OCS Liver is an FDA approved device for donation after circulatory death and donation after brain death donor livers.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on TMDX
About TMDX
About the author

Four Companies Worth Buying Before Earnings
- Investment Opportunity: The video highlights four companies that remain worth buying before their earnings reports, drawing investor interest and potentially leading to price fluctuations post-report.
- Market Dynamics: Stock prices as of January 27, 2026, indicate that these companies' market performance may be influenced by the upcoming earnings announcements, prompting investors to stay vigilant.
- Video Content: The video aims to provide in-depth analysis of these companies, assisting viewers in making informed investment decisions, particularly during this critical pre-earnings period.
- Subscription and Offers: The video encourages viewers to subscribe to the channel and click on a special offer link, indicating the content creator's intent to enhance viewer engagement by providing valuable insights.

TransMedics Signs Long-Term Lease for New HQ, Expected to Create 600 Jobs
- New Headquarters Development: TransMedics has signed a long-term lease at Assembly Innovation Park in Somerville and acquired adjacent land, planning to relocate by 2028 to integrate its corporate, research, and manufacturing capabilities, thereby enhancing its global expansion potential.
- Talent Attraction Strategy: The establishment of the new headquarters will provide TransMedics with a world-class working environment, aiding the company in attracting and retaining top talent to support its strategic goals for global expansion and innovation transformation.
- Tax Incentive Program: Massachusetts is offering up to $18 million in tax incentives through the Life Sciences Center, expected to create 600 new full-time jobs between 2026 and 2031, further driving local economic growth.
- Local Economic Impact: The Somerville city government is providing up to $18 million in tax relief, projected to generate $75 million in new local tax revenues over ten years, promoting regional employment and economic development.






